50 completed, 14 terminated, 9 active not recruiting, 6 recruiting. 88 Phase 1, 33 Phase 2.
Follow tremelimumab: new trials by email Literature Review of tremelimumab trials Research Report on tremelimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab SC durvalumab + rHu, IV durvalumab, Tremelimumab - Solid Tumours | Phase 1 | Recruiting | AstraZeneca | 40 | 2026-03-31 | 2026-09-24 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Yoon Jun Kim | 24 | 2025-04-18 | 2025-05-14 |
| Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab SD-101, Cryotherapy, Tremelimumab - Hepatocellular Carcinoma | Phase 1 | Active not recruiting | University of California, San Diego | 16 | 2025-01-03 | 2026-07-28 |
| Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab - Mesothelioma | Phase 1 / Phase 2 | Recruiting | Baylor College of Medicine | 52 | 2024-07-03 | 2026-10-02 |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Angiography, Biopsy, Biospecimen Collection - Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Recruiting | Mayo Clinic | 16 | 2024-06-06 | 2026-05-13 |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC Durvalumab, Tremelimumab, SIRT - Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Active not recruiting | Jiping Wang, MD, PhD | 20 | 2023-04-21 | 2026-08-13 |
| Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) Novel combination of chemotherapy and immunotherapy - Cholangiocarcinoma | Phase 1 / Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2023-01-30 | 2024-11-05 |
| An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas Recombinant Human Adenovirus Type 5 Injection - Malignant Melanomas | Phase 1 | Unknown | Fujian Cancer Hospital | 10 | 2022-10-27 | 2023-07-10 |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Tremelimumab - Bladder Cancer, High-Risk Cancer | Phase 1 / Phase 2 | Withdrawn | University of British Columbia | 2021-09-01 | 2023-10-31 | |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide - Small Cell Lung Carcinoma | Phase 1 | Terminated | University of Nebraska | 1 | 2020-09-25 | 2023-08-28 |
| TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer Tremelimumab, Durvalumab, Bladder radiation - Bladder Cancer | Phase 1 | Withdrawn | Daniel George, MD | 2020-06-01 | 2020-07-07 | |
| Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Durvalumab, Durvalumab and Tremelimumab, Y-90 Selective Internal Radiation Therapy (SIRT) - Colorectal Cancer | Phase 1 | Withdrawn | University of Colorado, Denver | 2019-08-01 | 2024-12-09 | |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Durvalumab, Tremelimumab, Olaparib Pill - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2019-06-06 | 2026-04-01 |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer Tremelimumab, Durvalumab, Paclitaxel - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 53 | 2019-05-01 | 2025-03-06 |
| Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Durvalumab, Selumetinib, Tremelimumab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2019-04-01 | 2026-10-23 |
| Durvalumab and Tremelimumab for Pediatric Malignancies Durvalumab / Tremelimumab Combination Therapy - Pediatric Cancer, Solid Tumor Pediatric | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 50 | 2019-03-07 | 2026-09-29 |
| Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment Durvalumab, Tremelimumab, Pemetrexed - Stage III NSCLC | Phase 1 | Terminated | The Netherlands Cancer Institute | 18 | 2018-12-28 | 2024-11-06 |
Showing 20 of 88. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (12) · Carcinoma, Non-Small-Cell Lung (10) · Melanoma (10) · Colorectal Neoplasms (8) · Breast Neoplasms (7) · Carcinoma, Hepatocellular (7) · Small Cell Lung Carcinoma (6) · Lung Neoplasms (5) · Prostatic Neoplasms (5) · Urinary Bladder Neoplasms (5) · Biliary Tract Neoplasms (4) · Carcinoma, Renal Cell (4) · Diabetes Mellitus, Insulin-Dependent, 12 (4) · Neoplasms (4) · Ovarian Neoplasms (4)
AstraZeneca (14) · MedImmune LLC (9) · Ludwig Institute for Cancer Research (5) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · University of Wisconsin, Madison (3) · Abramson Cancer Center at Penn Medicine (2) · City of Hope Medical Center (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Memorial Sloan Kettering Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · The Netherlands Cancer Institute (2) · A.J.M. van den Eertwegh (1) · Anwaar Saeed (1) · Asan Medical Center (1)
United States (63) · France (11) · Canada (9) · South Korea (9) · United Kingdom (7) · Japan (5) · Netherlands (5) · Spain (5) · Taiwan (5) · Australia (4) · Belgium (4) · Germany (4) · Italy (4) · China (2) · Israel (2)
Tim F Greten, M.D. (3) · Adam Burgoyne, MD, PhD (1) · Alberto A Chiappori, MD (1) · Alexander M. Lesokhin, MD (1) · Anwaar Saeed, MD (1) · Apar Ganti, MD (1) · Ashok Gupta, MD, PhD (1) · Catherine Shu, MD (1) · Craig L Slingluff, Jr., MD (1) · Cristina P. Rodriguez (1) · Daneng Li (1)
PMID 23171508, PMID 24907635, PMID 26858122, PMID 27816492, PMID 28923358, PMID 29942666, PMID 30578687, PMID 30642290, PMID 30688989, PMID 32169783, PMID 32269052, PMID 32586937, PMID 32620213, PMID 32816849, PMID 33852104, PMID 34772758, PMID 34953624, PMID 35521657, PMID 35611499, PMID 35671201, PMID 35699623, PMID 35857579, PMID 36754451, PMID 36948505, PMID 37146752, PMID 37489066, PMID 37563240, PMID 38378868, PMID 39043009, PMID 40091844, PMID 40273550, PMID 40399487, PMID 40795480, PMID 42190158, PMID 42222420, PMID 42310313, PMID 42586218
2015 (3), 2017 (3), 2016 (1), 2018 (1), 2023 (1), 2025 (1), P30CA015704 (1), P30CA033572 (1)